Periocular gene transfer of sFlt-1 suppresses ocular neovascularization and vascular endothelial growth factor-induced breakdown of the blood-retinal barrier

Human Gene Therapy

Volumn 14, Issue 2, 2003, Pages 129-141

  Gehlbach, Peter ^a   Carrion, Miguel ^b   Wei, Lisa ^b   Campochiaro, Peter A ^a   Demetriades, Anna Maria ^a   Yamamoto, Satoru ^a   Deering, Tye ^a   Xiao, Wei Hong ^a   Duh, Elia J ^a   Yang, Hoseong S ^a   Lai, Hong ^a   Kovesdi, Imre ^b  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b GENVEC INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOVIRUS VECTOR; PIGMENT EPITHELIUM DERIVED FACTOR; PROTEIN SFLT 1; UNCLASSIFIED DRUG; VASCULOTROPIN; VASCULOTROPIN RECEPTOR 1;

ADENOVIRUS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD RETINA BARRIER; BLOOD VESSEL PERMEABILITY; BRUCH MEMBRANE; CONTROLLED STUDY; DIABETIC RETINOPATHY; DISEASE ASSOCIATION; DRUG DELIVERY SYSTEM; FEMALE; GENE REPRESSION; GENE THERAPY; GENE TRANSFER; MOUSE; NEWBORN; NONHUMAN; PIGMENT EPITHELIUM; RETINA ISCHEMIA; RETINA MACULA EDEMA; RETINA NEOVASCULARIZATION; RETINA TEAR; SUBRETINAL NEOVASCULARIZATION; VIRAL GENE DELIVERY SYSTEM;

ADENOVIRIDAE; ANIMALS; BLOOD-RETINAL BARRIER; ENDOTHELIAL GROWTH FACTORS; EXTRACELLULAR MATRIX PROTEINS; EYE; GENE TRANSFER TECHNIQUES; GENES, REPORTER; GENETIC VECTORS; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; LYMPHOKINES; MICE; NEOVASCULARIZATION, PATHOLOGIC; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTORS;

ADENOVIRIDAE; ANIMALIA;

EID: 0037248088     PISSN: 10430342     EISSN: None     Source Type: Journal    
DOI: 10.1089/104303403321070829     Document Type: Article

References (54)

1. AIELLO, L.P., PIERCE, E.A., FOLEY, E.D., TAKAGI, H., CHEN, H., RIDDLE, L., FERRARA, N., KING, G.L., and SMITH, L.E.H. (1995). Suppression of retinal neovascularization in vivo by inhibition of vascular endothelial growth factor (VEGF) using soluble VEGF-receptor chimeric proteins. Proc. Natl. Acad. Sci. U.S.A. 92, 10457-10461.
2. ALI, R.R., REICHEL, M.B., DE ALWIS, M., KANUGA, N., KINNON, C., LEVINSKY, R.J., HUNT, D.M., BHATTACHARYA, S.S., and THRASHER, A.J. (1998). Adeno-associated viurs gene transfer to mouse retina. Hum. Gene Ther. 9, 81-86.
3. BAINBRIDGE, J., MISTRY, A., ALWIS, M.D., PALEOLOG, E., BAKER, A., THRASHER, A.J., and ALI, R.R. (2002). Inhibition of retinal neovascularization by gene transfer of soluble VEGF receptor sFlt-1. Gene Ther. 9, 320-326.
4. BENNETT, J., DUAN, D., ENGELHARDT, J.F., and MAGUIRE, A.M. (1997). Real-time, noninvasive in vivo assessment of adeno-associated virus-mediated retinal transduction. Invest. Ophthalmol. Vis. Sci. 38, 2857-2863.
5. BENNETT, J., MAGUIRE, A.M., CIDECIYAN, A.V., SCHNELL, M., GLOVER, E., ANAND, V., ALELMAN, T.S., CHIRMULE, N., GUPTA, A.R., HUANG, Y., GAO, G.P., NYBERG, W.C., TAZELAAR, J., HUGHES, J., WILSON, J.M., and JACOBSON, S.G. (1999). Stable transgene expression in rod photoreceptors after recombinant adeno-associated virus-mediated gene transger to monkey retina. Proc. Natl. Acad. Sci. U.S.A. 96, 9920-9925.
6. BRANCH VEIN OCCLUSION STUDY GROUP (1984). Argon laser photocoagulation for macular edema in branch vein occlusion. Am. J. Ophthalmol. 98, 271-282.
7. BROUGH, D.E., LIZONOVA, A., HSU, C., KULESA, V.A., and KOVESDI, I. (1996). A gene transfer vector-cell line system for complete functional complementation of adenovirus early regions E1 and E4. J. Virol. 70, 6497-6501.
8. CENTRAL VEIN OCCLUSION STUDY GROUP (1995). Evaluation of grid pattern photocoagulation for macular edema in central vein occlusion. The central vein occlusion study group M report. Ophthalmology 102, 1425-1433.
9. CHINNADURAI, G., CHINNADURAI, S., and BUSCA, J. (1979). Physical mapping of a large-plaque mutation of adenovirus type 2. J. Virol. 32, 623-628.
10. DEREVJANIK, N.L., VINORES, S.A., XIAO, W.-H., MORI, K., TURON, T., HUDISH, T., DONG, S., and CAMPOCHIARO, P.A. (2002). Quantitative assessment of the integrity of the blood-retinal barrier in mice. Invest. Ophthalmol. Vis. Sci. 43, 2462-2467.
11. DIABETIC RETINOPATHY STUDY RESEARCH GROUP (1985). Photocoagulation for diabetic macular edema, ETDRS Report No. 1. Arch. Ophthalmol. 103, 1644-1652.
12. DUH, E.J., YANG, H.S., SUZUMA, I., MIYAGI, M., YOUNGMAN, E., MORI, K., KATAI, M., YAN, L., SUZUMA, K., WEST, K., DAVARYA, S., TONG, P., GEHLBACH, P., PEARLMAN, J., CRABB, J.W., AIELLO, L.P., CAMPOCHIARO, P.A., and ZACK, D.J. (2002). Pigment epithelium-derived factor suppresses ischemia-induced retinal neovascularization and VEGF-induced migration and growth. Invest. Ophthalmol. Vis. Sci. 43, 821-829.
13. EDELMAN, J.L., and CASTRO, M.R. (2000). Quantitative image analysis of laser-induced choroidal neovascularization in rat. Exp. Eye Res. 71, 523-533.
14. FLANNERY, J.G., ZOLOTUKHIN, S., VAQUERO, M.I., LAVAIL, M.M., MUZYCZKA, N., and HAUSWIRTH, W.W. (1997). Efficient photoreceptor-targeted gene expression in vivo by recombinant adeno-associated virus. Proc. Natl. Acad. Sci. U.S.A. 94, 6916-6921.
15. FOLKMAN, J. (1995). Angiogenesis in cancer, vascular, rheumatoid, and other diseases. Nat. Med. 1, 27-31.
16. FORSYTHE, J.A., JIANG, B.-H., IYER, N.V., AGANI, F., LEUNG, S.W., KOOS, R.D., and SEMENZA, G. (1996). Activation of vascular endothelial growth factor gene transcription by hypoxia-inducible factor 1. Mol. Cell. Biol. 16, 4604-4613.
17. GERBER, H.-P., CONDORELLI, F., PARK, J., and FERRARA, N. (1997). Differential transcriptional regulation of the two vascular endothelial growth factor receptor genes. Flt-1, but not Flk-1/KDR, is up-regulated by hypoxia. J. Biol. Chem. 272, 23659-23667.
18. GOLDMAN, C.K., KENDALL, R.L., CABRERA, G., SOROCEANU, L., HEIKE, Y., GILLESPIE, G.Y., SIEGAL, G.P., MAO, X., BETT, A.J., HUCKLE, W.R., THOMAS, K.A., and CURIEL, D.T. (1998). Paracrine expression of a native soluble vascular endothelial growth factor receptor inhibits tumor growth, metastasis, and mortality rate. Proc. Natl. Acad. Sci. U.S.A. 95, 8795-8800.
19. GUYER, D.R., MARTIN, D.M., KLEIN, M., HALLER, J., and THE EYE TECH STUDY GROUP. (2001). Anti-VEGF therapy in patients with exudative age-related macular degeneration. Invest. Ophthalmol. Vis. Sci. 42(Suppl), S522.
20. HANGAI, M., MOON, Y.S., KITAYA, N., CHAN, C.K., WU, D.-Y., PETERS, K.G., RYAN, S.J., and HINTON, D.R. (2001). Systemically expressed soluble Tie2 inhibits intraocular neovascularization. Hum. Gene Ther. 12, 1311-1321.
21. HE, Y., SMITH, S.K., DAY, KA., CLARK, D.E., LICENCE, D.R., and CHARNOCK-JONES, D.S. (1999). Alternative splicing of vascular endothelial growth factor (VEGF)-R1 (FLT-1) pre-mRNA is important for the regulation of VEGF activity. Mol. Endocrinol. 13, 537-545.
22. HONDA, M., SAKAMOTO, T., ISHIBASHI, T., INOMATA, H., and UENO, H. (2000). Experimental subretinal neovascularization is inhibited by adenovirus-mediated soluble VEGF.flt-1 receptor gene transfection: A role of VEGF and possible treatment for SRN in age-related macular degeneration. Gene Ther. 7, 978-985.
23. 2 homeostasis by hypoxia-inducible factor 1alpha. Genes Dev. 12, 149-162.
24. KENDALL, R.L., WANG, G.L., and THOMAS, K.A. (1996). Identification of a natural soluble form of the vascular endothelial growth factor receptor, FLT-1, and its heterodimerization with KDR. Biochem. Biophys. Res. Commun. 226, 324-328.
25. KONG, H.-L., HECHT, D., SONG, W., KOVESDI, I., HACKETT, N.R., YAYON, A., and CRYSTAL, R.G. (1998). Regional suppression of tumor growth by in vivo transfer of a cDNA encoding a secreted form of the extracellular domain of the flt-1 vascular endothelial growth factor receptor. Hum. Gene Ther. 9, 823-833.
26. KWAK, N., OKAMOTO, N., WOOD, J.M., and CAMPOCHIARO, P.A. (2000). VEGF is an important stimulator in a model of choroidal neovascularization. Invest. Ophthalmol. Vis. Sci. 41, 3158-3164.
27. LAI, C.-C., WU, W.-C., CHEN, S.-L., XIAO, X., TSAI, T.-C., HUAN, S.-J., CHEN, T.-L., TSAI, R.J.-F., and TSAO, Y.-P. (2001a). Suppression of choroidal neovascularization by adeno-associated virus vector expressing angiostatin. Invest. Ophthalmol. Vis. Sci. 42, 2401-2407.
28. LAI, C.-M., BRANKOV, M., ZAKNICH, T., LAI, Y.K.-Y., SHEN, W.-Y., CONSTABLE, I.J., KOVESDI, I., and RAKOCZY, P.E. (2001b). Inhibition of angiogenesis by adenovirus-mediated sFlt-1 expression in a rat model of corneal neovascularization. Hum. Gene Ther. 12, 1299-1310.
29. LAI, Y.K., SHEN, W.Y., BRANKOV, M., LAI, C.M., CONSTABLE, I.J., and RAKOCZY, P.E. (2002). Potential long-term inhibition of ocular neovascularization by recombinant adeno-associated virus-mediated secretion gene therapy. Gene Ther. 9, 804-813.
30. LUTTY, G.A., MCLEOD, S.D., MERGES, C., DIGGS, A., and PLOUET, J. (1996). Localization of vascular endothelial growth factor in human retina and choroid. Arch. Opthalmol. 114, 971-977.
31. MAHASRESHTI, P.J., NAVARRO, J.G., KATARAM, M., WANG, M.H., CAREY, D., SIEGAL, G.P., BARNES, M.N., NETTELBECK, D.M., ALVAREZ, R.D., HEMMINKI, A., and CURIEL, D.T. (2001). Adenovirus-mediated soluble FLT-1 gene therapy for ovarian carcinoma. Clin. Cancer Res. 7, 2057-2066.
32. MILLER, J.W., ADAMIS, A.P., SHIMA, D.T., D'AMORE, P.A., MOULTON, R.S., O'REILLY, M.S., FOLKMAN, J., DVORAK, H.F., BROWN, L.F., BERSE, B., YEO, T.-K, and YEO, K.-T. (1994). Vascular endothelial growth factor/vascular permeability factor is temporally and spatially correlated with ocular angiogenesis in a primate model. Am. J. Pathol. 145, 574-584.
33. MIYOSHI, H., TAKAHASHI, M., GAGE, F.H., and VERMA, I.M. (1997). Stable and efficient gene transfer into the retina using an HIV-based lentiviral vector. Proc. Natl. Acad. Sci. U.S.A. 94, 10319-10323.
34. MORI, K., ANDO, A., GEHLBACH, P., NESBITT, D., TAKAHASHI, K., GOLDSTEEN, D., PENN, M., CHEN, T., MORI, K, MELIA, M., PHIPPS, S., MOFFAT, D., BRAZZELL, K., LIAU, G., DIXON, K.H., and CAMPOCHIARO, P.A. (2001a). Inhibition of choroidal neovascularization by intravenous injection of adenoviral vectors expressing secretable endostatin. Am. J. Pathol. 159, 313-320.
35. MORI, K., DUH, E., GEHLBACH, P., ANDO, A., TAKAHASHI, K., PEARLMAN, J., MORI, K., YANG, H.S., ZACK, D.J., ETTYREDDY, D., BROUGH, D.E., WEI, L.L., and CAMPOCHIARO, P.A. (2001b). Pigment epithelium-derived factor inhibits retinal and choroidal neovascularization. J. Cell. Physiol. 188, 253-263.
36. MORI, K., GEHLBACH, P., ANDO, A., WAHLIN, K., GUNTHER, V., MCVEY, D., WEI, L., and CAMPOCHIARO, P.A. (2002a). Intraocular adenoviral vector-mediated gene transfer is increased in proliferative retinopathies. Invest. Ophthalmol. Vis. Sci. 43, 1610-1615.
37. MORI, K., GEHLBACH, P., YAMAMOTO, S., DUH, E., ZACK, D.J., LI, Q., BERNS, K.I., RAISLER, B.J., HAUSWIRTH, W.W., and CAMPOCHIARO, P.A. (2002b). AAV-mediated gene transfer of pigment epithelium-derived factor inhibits choroidal neovascularization. Invest. Ophthalmol. Vis. Sci. 43, 1994-2000.
38. OKAMOTO, N., TOBE, T., HACKETT, S.F., OZAKI, H., VINORES, M.A., LAROCHELLE, W., ZACK, D.J., and CAMPOCHIARO, P.A. (1997). Transgenic mice with increased expression of vascular endothelial growth factor in the retina: A new model of intraretinal and subretinal neovascularization. Am. J. Pathol. 151, 281-291.
39. OLSSON, J.E., GORDON, J.W., PAWLYK, B.S., ROOF, D., HAYES, A., MOLDAY, R.S., MUKAI, S., COWLEY, G.S., BERSON, E.L., and DRYJA, T.P. (1992). Transgenic mice with a rhodopsin mutation (Pro23His): A mouse model of autosomal dominant retinitis pigmentosa. Neuron 9, 815-830.
40. OZAKI, H., HAYASHI, H., VINORES, S.A., MOROMIZATO, Y., CAMPOCHIARO, P.A., and OSHIMA, K. (1997). Intravitreal sustained release of VEGF causes retinal neovascularization in rabbits and breakdown of the blood-retinal barrier in rabbits and primates. Exp. Eye Res. 64, 505-517.
41. OZAKI, H., SEO, M.-S., OZAKI, K., YAMADA, H., YAMADA, E., HOFMANN, F., WOOD, J., and CAMPOCHIARO, P.A. (2000). Blockade of vascular endothelial cell growth factor receptor signaling is sufficient to completely prevent retinal neovascularization. Am. J. Pathol. 156, 679-707.
42. PIERCE, E.A., AVERY, R.L., FOLEY, E.D., AIELLO, L.P., and SMITH, L.E.H. (1995). Vascular endothelial growth factor/vascular permeability factor expression in a mouse model of retinal neovascularization. Proc. Natl. Acad. Sci. U.S.A. 92, 905-909.
43. QAUM, T., XU, Q., JOUSSEN, A.M., CLEMENS, M.W., QIN, W., MIYAMOTO, K., HASSESSIAN, H., WIEGAND, S.J., RUDGE, J., YANCOUPOULOS, G.D., and ADAMIS, A.P. (2001). VEGF-initiated blood-retinal barrier breakdown in early diabetes. Invest. Ophthalmol. Vis. Sci. 42, 2408-2413.
44. SARRA, G.M., STEPHENS, C., DE ALWIS, M., BAINBRIDGE, J.W., SMITH, A.J., THRASHER, A.J., and ALI, R.R. (2001). Gene replacement therapy in the retinal degeneration slow (rds) mouse: the effect on retinal degeneration following partial transduction of the retina. Hum. Mol. Genet. 10, 2353-2361.
45. SCHWARTZ, S.D., BLUMENKRANZ, M., ROSENFELD, P.J., MILLER, J.W., HALLER, J., FISH, G., LOBES, L., SINGERMAN, L., GREEN, W.L., and REIMANN, J. (2001). Safety of rhuFab V2, an anti-VEGF antibody fragment, as a single intravitreal injection in subjects with neovascular age-related macular degeneration. Invest. Ophthalmol. Vis. Sci. 42(Suppl), S522.
46. SEO, M.-S., KWAK, N., OZAKI, H., YAMADA, H., OKAMOTO, N., FABBRO, D., HOFMANN, F., WOOD, J.M., and CAMPOCHIARO, P.A. (1999). Dramatic inhibition of retinal and choroidal neovascularization by oral administration of a kinase inhibitor. Am. J. Pathol. 154, 1743-1753.
47. SHIOSE, S., SAKAMOTO, T., YOSHIKAWA, H., HATA, Y., KAWANO, Y., ISHIBASHI, T., INOMATA, H., TAKAYAMA, K., and UENO, H. (2000). Gene transfer of a soluble receptor of VEGF inhibits the growth of experimental eyelid malignant melanoma. Invest. Ophthalmol. Vis. Sci. 41, 2395-2403.
48. SMITH, L.E.H., KOPCHICK, J.J., CHEN, W., KNAPP, J., KINOSE, F., DALEY, D., FOLEY, E., G., S.R., and SCHAEFFER, J.M. (1997). Essential role of growth hormone in ischemia-induced retinal neovascularization. Science 276, 1706-1709.
49. SMITH, L.E.H., WESOLOWSKI, E., MCLELLAN, A., KOSTYK, S.K., D'AMATO, R., SULLIVAN, R., and D'AMORE, P.A. (1994). Oxygen-induced retinopathy in the mouse. Invest. Ophthalmol. Vis. Sci. 35, 101-111.
50. TAKAHASHI, T., NAKAMURA, T., HAYASHI, A., KAMEI, M., NAKABAYASHI, M., OKADA, A.A., TOMITA, N., DANEDA, Y., and TANO, Y. (2000). Inhibition of experimental choroidal neovascularization by overexpression of tissue inhibitor of metalloproteinases-3 in retinal pigment epithelium. Am. J. Ophthalmol. 130, 774-781.
51. TAKAYAMA, K., UENO, H., NAKANISHI, Y., SAKAMOTO, T., INOUE, K., SHIMIZU, K., OOHASHI, H., and HAI, N. (2000). Suppression of tumor angiogenesis and growth by gene transfer of a soluble form of vascular endothelial growth factor receptor into a remote organ. Cancer Res. 60, 2168-2177.
52. TOBE, T., OKAMOTO, N., VINORES, M.A., DEREVJANIK, N.L., VINORES, S.A., ZACK, D.J., and CAMPOCHIARO, P.A. (1998a). Evolution of neovascularization in mice with overexpression of vascular endothelial growth factor in photoreceptors. Invest. Ophthalmol. Vis. Sci. 39, 180-188.
53. TOBE, T., ORTEGA, S., LUNA, L., OZAKI, H., OKAMOTO, N., DEREVJANIK, N.L., VINORES, S.A., BASILICO, C., and CAMPOCHIARO, P.A. (1998b). Targeted disruption of the FGF2 gene does not prevent choroidal neovascularization in a murine model. Am. J. Pathol. 153, 1641-1646.
54. VINORES, S.A., YOUSSRI, A.I., LUNA, J.D., CHEN, Y.-S., BHARGAVE, S., VINORES, M.A., SCHOENFELD, C.-L., PENG, B., CHAN, C.-C., LAROCHELLE, W., GREEN, W.R., and CAMPOCHIARO, P.A. (1997). Upregulation of vascular endothelial growth factor in ischemic and non-ischemic human and experimental retinal disease. Histol. Histopathol. 12, 99-109.